ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$13.62 USD
-0.17 (-1.23%)
Updated May 21, 2024 04:00 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
ALX Oncology Holdings Inc. [ALXO]
Reports for Purchase
Showing records 21 - 28 ( 28 total )
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
SHIELD Platform Could Help Deepen Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Encouraging ALX148 Update at ESMO GI; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Advancing Pipeline as Planned; Clinical Updates Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Sell-off Unwarranted; Multiple Clinical Updates in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Expanding Pipeline With a First-in-Class SIRPá-Targeted Drug; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
A CD47 Player Leading the Fight Against Solid Tumors; Initiate With Buy and a $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S